Bonum Therapeutics, a leading biotech startup, is making significant strides towards the development of groundbreaking immunotherapy drugs as it prepares to double its headcount. The company is set to occupy the 11th floor of the prestigious new life science tower at 1150 Eastlake Ave. E., located near Seattle’s vibrant South Lake Union neighborhood.
CEO John Mulligan expressed his excitement about the move, highlighting the stunning views and the vibrant atmosphere that the new space will provide. Mulligan further revealed that Bonum Therapeutics seized this opportunity during the biotech downturn in 2022, demonstrating the company’s agility and strategic decision-making.
Located in close proximity to various biotech startups and life science research organizations like Fred Hutchinson Cancer Research and The Allen Institute, Bonum’s choice of location is strategic for collaboration and access to a supportive scientific community.
This move to new offices signifies the company’s ambition to expand rapidly. Mulligan plans to increase the current team of 31 employees and aims to double the headcount within the next few years. This growth trajectory will enable Bonum Therapeutics to amplify its research and development efforts, ultimately bringing innovative immunotherapy drugs to the market.
Bonum’s journey began in 2016 when Mulligan founded Good Therapeutics, a pioneer in designing cancer drugs with minimized side effects. In a groundbreaking acquisition in 2022, Roche acquired Good Therapeutics for an impressive $250 million, securing exclusive rights to the company’s most promising preclinical drug candidate.
As Bonum Therapeutics sets its sights on revolutionizing immunotherapy, the company’s move to new state-of-the-art offices symbolizes its commitment to scientific advancements and its unwavering dedication to improving patient lives through cutting-edge biotechnology.